Summary.-The effects are reported of a combination therapy of i.v. C. parvum and cyclophosphamide on the survival time and immune responses of patients with inoperable squamous-cell carcinoma of the bronchus. The immune status of the patients was evaluated by determining the antibody response to C. parvum, the E and EAC rosettes, the PHA response of blood lymphocytes, the skin-test reactivity to Candida and PPD, the response to DNCB and the chemotaxis and NBT-dye reduction capacity of neutrophil leucocytes.
IN NON-RESECTABLE squamous-cell carcinoma of the bronchus the survival time is low. Although some benefit may be achieved by irradiation and chemotherapy, the median survival time is only slightly increased (Carbone et al., 1970) . There has been evidence that stimulation of the immune system with bacterial toxins can favourably modify tumour growth (Nauts, 1969) . Corynebacterium parvum is known to be a potent stimulator of the immune system (Halpern et al., 1963) and its administration in combination with cytostatics was reported to be of value in animal tumour models (Fisher et al., 1975a) and in human neoplastic disease (Israel & Edelstein, 1975; Presant et al., 1976; Pinsky et al., 1978) . Israel and Edelstein (1975) noted a significant increase in the survival time of patients with carcinoma of the bronchus treated with a 5-drug combination chemotherapy and C. parvum s.c. as compared to the survival time of similar cases treated with cytostatics alone. They also found that C. parvum improved the "hematopoietic tolerance to chemotherapy, i.e. the number of therapeutic interruptions due to leukopenia could be reduced to half in the C. parvum-treated group. Their observations were confirmed by others (Dimitrov et al., 1978) . It is well established that chemotherapy not only decreases the number of peripheral white cells, but also influences the functions of these cells (Haskell, 1977) .
This report describes a study on the effect of C. parvum on the survival time and the function of the immune system of cyclophosphamide-treated patients suffering from inoperable squamous-cell carcinoma of the bronchus. Cyclophosphamide (CY) was given i.v. either alone at fortnightly intervals or in combination with C. parvum. Regarding the route of administration it is known from animal studies that the effect of this immunostimulant is most marked after i.v. or i.p. injection, whereas the s.c. route was much less effective (Woodruff et al., 1975; Fisher et al., 1975b) . C. parvum was therefore given by i.v. infusion. It was infused a few hours after CY, since it has been reported that an effective therapy regime could be achieved by administration of both CY and C. parvum on the same day (Fisher et cal., 1975b) . As it is still a matter of conjecture whether CY alone given i.v. is of value in the treatment of squamouscell carcinoma of the bronchus (Cohen, 1978) we also included in this study a patient group left untreated. This latter group enabled us to evaluate not only the effect of the given dose of CY on the survival time, but also on the functions of the immune system.
During the study it became evident that the survival time of patients treated with the combination therapy of C. parvum and CY was significantly shorter than that recorded in the other 2 patient groups. This forced us to terminate the study prematurely, so that data from a limited number of patients are reported.
PATIENTS AND METHODS
Patients.-Twenty-three male patients with non-resectable squamous-cell carcinoma of the bronchus (Stage Ilb and III) and with a Karnofsky performance score of 80 to 100 were studied, after informed consent had been obtained. The median age was 62 years, range 45-76. None of the patients had received previous chemotherapy or radiotherapy, or had contraindications for C. parvum treatment, such as autoimmune disease, hypertension, cardiovascular disease, severe pulmonary insufficiency, intercurrent infections or the use of barbiturates.
The patients were randomly allocated to 3 groups, using a computer-generated pseudorandom (Weening et al., 1974) . Neutrophil chemotaxis was determined according to Wilkinson (1974) (Hammersten, Merck, Darm- stadt, Germany) in Gey solution. The distance of migration into the membranes was recorded using the leading front method (Zigmond & Hirsch, 1973) . The quantitative NBT-dye reduction capacity of the neutrophils was determined according to the method described by Drexhage et al. (1978) but using 5 x 106 leucocytes and foetal-calfserum-supplemented medium. The reaction was allowed to proceed for 10 min. The optical densities (OD) at 509 nm of 2 ml 42 pyridine extracts of the granulocytes were determined (spectrophotometer, Eppendorf 1101 M, Hamburg, Germany).
RESULTS
The course of the Karnofsky performance score recorded in each patient and their survival times are shown in Fig. 1 . Median survival times were 125 days in the group treated with the combination therapy, 245 days after therapy with CY only, and 277 days in patients left untreated. The difference between the combination therapy and the CY therapy group was significant at a 5 % level (Wilcoxon test). It has been reported that only a difference significant at the 1% level would merit a decision to stop a trial (Pocock, 1978) but continuing was unjustifiable in our opinion, since considerable side effects were found (Table I) . A febrile response was evident in almost all patients, whereas chills, an increased pulse rate and mild dyspnoea were seen after most of the C. parvum infusions. A few patients had nausea and vomiting, changes in blood pressure and headache. All these side effects subsided within 24 h. No obvious decrease in the complaints was noted after a second or third C. parvum infusion.
One of the patients in the C. parvumtreated group died 10 h after the second administration. Thorough medical examination before entrance into the trial of this patient had not revealed any contraindication for C. parvum therapy. However, at necropsy an old myocardial infarction and arteriosclerotic coronary insufficiency were found to be present.
Antibodies to C. parvum were measured 5 days before and 12 days after the first administration. Ratios of post-to pretreatment titres are given in Fig. 2 . As can be seen, all patients who had received C. parvum showed a rise in titre, whereas in the 2 other groups only 1 and 2 patients exhibited a ratio of 1-1*5.
The total white cell, lymphocyte and the E-and EAC-rosette counts before and after treatment are listed in Table II therapy. It is of interest that in the latter 9/9 6/6 2/3 group the dose of CY had to be reduced as 8/9 5/6 2/3 many times as in the group treated with 6/9 4/5 0/3 CY alone (i.e. in 20% of the administra-5/6 2/6 2/3 tions). 4/9 3/6 2/3
The blastogenic response of blood lymphocytes to PHA was significantly 3/9 1/6 0/3 lower in the carcinoma patients than in healthy individuals (Table III) . No changes in PHA response were induced by I between the counts cytostatic treatment alone or cytostatic ichogenic carcinoma treatment in combination with C. parvum. hose of healthy indi-
The skin reactivity to Candida and treated with CY the PPD was also studied in these patients (Candida 61% and PPD 35% positive). In patients left without cytostatic and/or immunotherapy, the diameter of induration of the skin tests to these antigens showed a tendency to decline in the 2-month follow up, but the number of tests was too small for statistical evaluation.
With regard to the DNCB sensitization, no differences were found between the 3 groups of patients 14 days after sensitization, 70% of the patients in all 3 groups had become sensitive. At Day 70, 4/4 untreated patients had become sensitive, whereas in the 2 other groups 2/3 (combination therapy) and 2/5 (cytostatic therapy alone) responded to a DNCB challenge, but again the number of tests was too small for statistical evaluation.
The chemotaxis and the NBT-dye reduction capacity of neutrophil leucocytes of the carcinoma patients were comparable to those of healthy individuals. Whatever therapy the patients received, it had no influence on the chemotaxis or NBT-dye reduction test.
DISCUSSION
It became evident during this study that bronchial carcinoma patients treated with a combination therapy of i.v. C. parvum and CY showed a poor survival time. Moreover the treatment with C. parvum produced severe side effects during the first few hours after administration. Similar side effects were reported by Fisher et al. (1976) . Decreases in these side effects after repeated administrations as described by Israel (1974) were not found.
The immune status of the carcinoma patients was compared with that of healthy individuals. No differences were found regarding the number of peripheral white cells, lymphocytes, E and EAC rosettes, skin reactivity to Candida and PPD, ability to become sensitized to DNCB and the functions of neutrophil leucocytes as measured by chemotaxis and the quantitative NBT-dye reductions assay. However, the PHA blastogenesis was lower in the carcinoma patients. Al-Sarraf et al. (1972) and Thatcher et al. (1979) also demonstrated that the in vitro blastogenic transformation of lymphocytes by PHA was impaired in patients with solid tumours, especially with advanced neoplasia. Regarding the number of lymphocytes and T cells in tumourbearing patients, there is much confusion in the literature. Some investigators report normal ranges of T lymphocytes (Wybran & Fudenberg, 1976; Middlekoop et al., 1976) whereas others find decreased numbers (Dellon et al., 1975; Roberts et al., 1977) mostly depending on technical variables. The suppression of neutrophil function in carcinoma patients, described by Bauim (I1975), was not confirmed in this study.
To evaluate the effect of the cytostatic therapy and the combination therapy on the immune status of the patients, we investigated the described parameters after one administration of CY and C. parvum and after 2 months of therapy.
In patients left untreated no significant change was found in any of the immune parameters studied in the 2-month follow up, though the skin reactivity to PPD and Candida tended to decline. This is in agreement with the findings of Brugarolas et al. (1973) who reported a close relationship between the impairment of delayed skin reactivity and the extent of the disease.
Patients treated with CY only showed a survival time comparable with that of untreated patients. This indicates the ineffectiveness of this type of cytostatic treatment. The impaired PHA response found in patients before therapy did not change after CY administration. This continued suppression of PHA response may reflect the poor survival time, since Cheema & Hersh (1971) reported a rebound of in vitro PHA blastogenesis in patients showing a regression of their malignancy after chemotherapy. Regarding the responsiveness to DNCB the administration of CY has been shown to be able to influence the development of delayed hypersensitivity in experimental animals. Suppression and enhancement of the induction of delayed hypersensitivity have been reported, depending on the dose and schedule of the CY administered (Turk et al., 1976) . It is evident that in our study the influence of CY on T-lymphocyte function was minimal.
WVith regard to the addition of C. parvum immunotherapy to cytostatic treatment, no effect on any of the immune parameters was detected, though a normal antibody response to C. parrum was noted. It became clear over the last few years that the immunostimulatory effects of anaerobic coryneform bacteria depends especially on their ability to stimulate the functions of cells of the mononuclear phagocyte system (Wilkinson, 1975) . Therefore we also studied the effect of 7.5 mg C. parvumI/m2 i.v. on 2 particular functions of blood monocytes (i.e. spreading and antibody-dependent cytotoxicity) in a few patients suffering oatcell carcinoma of the bronchus. The results obtained in these C. parvuminfused patients were again not different from the results obtained in non-infused patients when tested at 14 days (unpublished results).
The negative results in the C. parvumand CY-treated patients are in sharp contrast to the positive results reported by Israel & Edelstein (1975) and Dimitrov et al. (1978) . However, they used a 5-drug combination chemotherapy and administered C. parvum s.c. Probably the route of administration is of importance. Pinsky et al. (1978) also reported a beneficial effect of s.c. C. parvum in advanced carcinoma of the breast, and preliminary results of a similar treatment in patients with a carcinoma of the cervix uteri in our hospital show an enhanced response to DNCB (to be published). There are also indications that the dose of the i.v. C. parvum is of importance. Using a low dose (2 mg/M2) Thatcher et al. (1979) reported an increase in T-cell numbers and PAH blastogenesis one week after a single immunization, whereas Minton et al. (1976) found no increase in these parameters in patients with a carcinoma of the breast after an infusion of a higher dose (5 mg C. parvum/m2). Furthermore, the interval between the administration of Cy and i.v. C. parvum used in this study (2 h) may have been too small. Extremely toxic effects and little anti-tumour activity have been reported in mice when the interval was zero (Currie & Bagshawe, 1970) . However, in other animal studies, effective therapy regimes could be achieved when both agents were given on the same day (Fisher et at., 1975b) . The anti-tumour activity of i.v. C. parvum is probably stronger when given 4 days after CY (Scott, 1979) .
In conclusion, our results indicate that one must be very careful in the use of a relatively high dose of i.v. C. parvum in combination with chemotherapy. Harmful effects can occur.
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